secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-138972
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter signs $4.25B deal to sell BioPharma Solutions to Advent/Warburg; CFO Saccaro resigns
--------------------------------------------------------------------------------

- Sold BioPharma Solutions (BPS) to Advent International and Warburg Pincus for $4.25B cash; net proceeds ~$3.4B after tax.
- Transaction expected to close H2 2023, subject to regulatory approvals; proceeds targeted for debt reduction.
- CFO Jay Saccaro resigns effective May 31, 2023; Brian Stevens named interim CFO (also remains CAO/Controller).
- BPS generated ~$600M revenue in FY2023; divestiture streamlines Baxter's focus on core medtech.
- Baxter reaffirms 2023 guidance except for potential impacts from proposed divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000119312523138972/0001193125-23-138972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000119312523138972/d406146d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer